English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The authors apologise for errors in the results reported in their above titled article published in the  European Journal of Endocrinology  2007  157   119–125 .  Due to a technical error, a number of fractures were not included in the database. In the cohort of 2750 participants, a total of 487 suffered a non-vertebral fracture (not 386 as stated in the article), and the incidence was 30.0 in women and 11.8 in men per 1000 person-years, respectively.  The main results were unchanged after re-analysis and no significant association was present between sex steroids and risk of non-vertebral fractures after adjustment for age in both sexes. Each 1 S.D. higher SHBG increased the risk of non-vertebral fracture by about 20% in women (HR 1.15; 95% CI 1.03–1.29) and men (HR 1.18; 95% CI 0.99–1.41) after adjustment for age, height, weight, smoking and physical activity. After adjustment for BMD, the increased risk was attenuated and no longer statistical significant in women (HR 1.07; 95% CI 0.96–1.21) and men (HR 1.12; 95% CI 0.94–1.34) respectively.

A prospective study of sex steroids, sex hormone-binding globulin, and non-vertebral fractures in women and men: the Tromsø Study